Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/171578
Title: CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation
Author: Honda, Kazufumi
Katzke, Verena A.
Husing, Anika
Okaya, Shinobu
Shoji, Hirokazu
Onidani, Kaoru
Olsen, Anja
Tjønneland, Anne
Overvad, Kim
Weiderpass, Elisabete
Vineis, Paolo
Muller, David
Tsilidis, Kostas
Palli, Domenico
Pala, Valeria
Tumino, Rosario
Naccarati, Alessio
Panico, Salvatore
Aleksandrova, Krasimira
Boeing, Heiner
Bueno de Mesquita, H. Bas
Peeters, Petra H.
Trichopoulou, Antonia
Lagiou, Pagona
Khaw, Kay Tee
Wareham, Nick
Travis, Ruth C.
Merino, Susana
Duell, Eric J.
Rodríguez Barranco, Miguel
Chirlaque, María Dolores
Barricarte, Aurelio
Rebours, Vinciane
Boutron-Ruault, Marie-Christine
Mancini, Francesca Romana
Brennan, Paul
Scelo, Ghislaine
Manjer, Jonas
Sund, Malin
Ohlund, Daniel
Canzian, Federico
Kaaks, Rudolf
Keywords: Càncer de pàncrees
Lipoproteïnes
Pancreas cancer
Lipoproteins
Issue Date: 15-Apr-2019
Publisher: Wiley
Abstract: Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. Our study provides a first prospective evaluation of an ApoA2 isoform ("ApoA2-ATQ/AT"), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken <= 6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and <= 18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of <= 6, >6-18 or <= 18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging.
Note: Reproducció del document publicat a: https://doi.org/10.1002/ijc.31900
It is part of: International Journal Of Cancer, 2019-04-15, Vol. 144, Issue 8, P. 1877-1887
URI: http://hdl.handle.net/2445/171578
Related resource: https://doi.org/10.1002/ijc.31900
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
HondaK.pdf311.76 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons